Mesoblast Limited
Level 38, 55 Collins Street
Melbourne, VIC 3000
Australia
February 10, 2025
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
via EDGAR
| RE: | Mesoblast Limited |
Registration Statement on Form F-3
Filed: February 5, 2025
Securities Act File No.: 333-284705
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, Mesoblast Limited (the “Registrant”) hereby respectfully requests acceleration of its Registration Statement on Form F-3 (File No. 333-284705), initially filed on February 5, 2025, so that it will become effective at 9:00 a.m. (Eastern time) on February 12, 2025, or as soon as practicable thereafter.
If you have any questions, or require any additional information, please do not hesitate to email Andrew Reilly, the Registrant’s outside counsel, at andrew.reilly@rimonlaw.com.
The Registrant hereby acknowledges that, if the Securities and Exchange Commission (or its staff, acting pursuant to delegated authority) (the “Commission”) declares the filing effective, such action:
| (i) | does not foreclose the Commission from taking any action with respect to the filing; |
| (ii) | does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and |
| (iii) | may not be asserted by the Registrant as a defence in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. |
| Very truly yours, | ||
| Mesoblast Limited | ||
| By: | /s/ Andrew Chaponnel | |
| Andrew Chaponnel | ||
| Interim Chief Financial Officer | ||